Federal Trade Commission v. Golden Sunrise Nutraceutical, Inc., et al.

Summary

The United States District Court for the Eastern District of California grants the Federal Trade Commission’s motion for summary judgment against Golden Sunrise Nutraceutical, Inc., Golden Sunrise Pharmaceutical, Inc., and Huu Tieu. The court holds that defendants lacked competent and reliable scientific substantiation for claims that their products could treat, mitigate, or cure COVID-19, cancer, and Parkinson’s disease, and that their representations concerning FDA approval and RMAT designation were false. The court also strikes unauthorized sur-replies and treats the corporate defendants’ failure to file a valid opposition as non-opposition.

Holdings

1. Defendants violated sections 5(a) and 12 of the FTC Act by advertising that their products could treat, mitigate symptoms of, or cure COVID-19, cancer, and Parkinson's disease without the level of substantiation required for those claims.
2. Defendants' representations that their products had been reviewed or approved by the FDA or designated as RMATs were false, material, and likely to mislead reasonable consumers, violating sections 5(a) and 12 of the FTC Act.
3. Defendant Tieu was individually liable for injunctive relief because he personally participated in the challenged conduct and had authority to control it; the FTC was not required to establish his knowledge because it sought only injunctive relief.
4. Golden Sunrise Nutraceutical, Inc. and Golden Sunrise Pharmaceutical, Inc. operated as a common enterprise and could be held jointly and severally liable.
5. Permanent injunctive relief was appropriate because the record demonstrated a cognizable danger of recurrent violations, and the proposed fencing-in provisions were permissible and reasonably limited.

Questions Presented

1. Whether Defendants' efficacy claims concerning treatment, mitigation, or cure of COVID-19, cancer, and Parkinson's disease violated sections 5(a) and 12 of the FTC Act because they lacked the required reasonable basis and substantiation.
2. Whether Defendants' representations that their products had FDA approval or RMAT designation were false, material, and likely to mislead consumers in violation of sections 5(a) and 12 of the FTC Act.
3. Whether Defendant Tieu was individually liable for injunctive relief based on his participation in or authority to control the challenged conduct.
4. Whether Golden Sunrise Nutraceutical, Inc. and Golden Sunrise Pharmaceutical, Inc. operated as a common enterprise and could be held jointly and severally liable.
5. Whether permanent injunctive relief was appropriate and whether the proposed scope of relief was permissible.

Disposition

other